Key Account Manager – Dallas TX – US
Key Account Manager – Dallas TX – US
Life Molecular Imaging (LMI) is a global, innovative R &D company focusing on the development and commercialization of molecular imaging radiopharmaceuticals for our approved F-18 amyloid PET tracer Neuraceq® and a pipeline of PET tracers in clinical development. LMI continues to grow at a steady pace creating the need for the following full-time position:
Responsible for business development and execution of strategies to effectively capitalize on sales opportunities in collaboration with Life Molecular Imaging’s goals and objectives. This individual will work in the specialized market of Neuro-Molecular Imaging within large specialty practices, specialty imaging facilities, and further expanding opportunities. The responsibilities below do not represent the entirety of the role but rather an overview of some of the key tasks.
Key Tasks and Responsibilities:
What we expect:
To be successful in this role, you must have the ability to manage change within a dynamic organization and an evolving health care marketplace. Have a sales background with experience in radiology/imaging, neurology sales, clinical neuroimaging, business development. Demonstrated ability to develop, cultivate and successfully manage high impact relationships, and projects. We are looking for others who are just as passionate as we are to improving the lives of those with Alzheimer’s and other neurodegenerative diseases.
What you can expect:
LMI is seeking candidates who are up for a challenge while being supported by their coworkers, managers, and other divisions of a global company. You will be able to make significant contributions through your expertise. You can expect what YOU do to matter, as all our employees are an integral part of a global organization as well as the communities we serve.
Life Molecular Imaging, Inc. is an Equal Opportunity Employer. We believe what we do and our culture of “More Than a Job. It’s Making Life Better” extends to creating a welcoming, safe, and inclusive work environment. If you have what it takes and the passion to make a difference, please visit our website to learn more. www.life-mi.com
PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.
Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.
SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program